Rongliflozin

Drug Profile

Rongliflozin

Alternative Names: HEC44616

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator HEC Pharm
  • Class Antihyperglycaemics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 05 Nov 2015 Preclinical trials in Type-2 diabetes mellitus in China (unspecified route) (HEC Pharm pipeline, November 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top